Instructional BiologyInstructional Biology Inc. says its newly filed technology platform brings together artificial intelligence, high fidelity biological processing, pathogen reduction technology, advanced drug delivery, and personalized biological modeling under a concept it calls "Instructional Medicine."
FOR IMMEDIATE RELEASE
OCEANSIDE, CA (September 10, 2026) — What if medicine could do more than block a symptom, shut down a receptor, or attack a single biological target? What if researchers could learn to understand more of the body's own biological language and use that information to guide how complex biological systems are studied, manufactured, delivered, and monitored?
Instructional Biology Inc. today announced the filing of U.S. Utility Patent Application No. 19/793,487, a parent application that brings together five independent technology systems spanning artificial intelligence, biological network modeling, high fidelity processing of fragile proteins and peptides, nonthermal pathogen reduction, advanced therapeutic delivery, and patient specific feedback. The company describes the integrated framework as Instructional Medicine.
The science is complex. The central idea is simpler: the body is not a machine with one switch. Modern medicines have transformed human health, and many work by interacting with a particular target. Yet hormones, proteins, peptides, receptors, enzymes, genes, and signaling pathways operate as connected networks. One signal can influence many others, and its biological meaning can depend on timing, structure, location, context, and the state of the surrounding system. Instructional Biology is developing tools intended to examine those relationships together rather than treating every signal as an isolated event.
Preserving the message, not just the ingredients
That distinction becomes especially important during manufacturing. Heating an egg changes the structure of its proteins, even though the same basic ingredients remain. Cooling the egg afterward does not restore the original structure. Instructional Biology's Markosian High Fidelity Bio Processing protocol is designed around preserving fragile biological structures during processing. The company uses the term Thermosensitive Peptidome, or TSP, for the collection of temperature sensitive signaling peptides and proteins it seeks to protect.
The newly filed patent application describes automated temperature controls, monitoring, structural integrity sensing, rapid cooling, and defined process limits. In plain language, the goal is not only to preserve ingredients. It is to preserve as much of the biological message carried by their structure as the process is designed and validated to retain.
Safety without heat
Pathogen safety creates another challenge. Some safety methods can expose biological material to conditions that may also affect delicate molecules. Instructional Biology's application therefore describes a nonthermal pathogen reduction approach, which the company calls the Laser Sieve. The proposed approach uses very short laser pulses and differences in physical response between viral structures and the biological material the process is intended to preserve. The concept can be compared to resonance: energy may interact more strongly with a structure that responds to a particular physical condition, rather than requiring broad heating of the entire material.
Organizing what is preserved
Preserving biological information is only part of the problem. Researchers also need a way to organize and reason across it. Instructional Biology has developed the Advanced Science AI Platform, or ASAP, together with the Signaling Cascade Knowledge Graph, or SCKG. The application describes a sixteen dimensional hyperbolic, or non Euclidean, representation intended to organize highly branching biological relationships.
The company's larger objective is to connect computational reasoning with physical manufacturing and delivery. A useful comparison is a navigation system connected to a vehicle. The map alone cannot move the car, the car alone does not know the route, and both need sensors reporting what is happening. Instructional Biology envisions a similar closed loop: map biological relationships, identify a constrained intervention, manufacture material while protecting relevant structure, deliver a payload, measure the resulting state, and feed new information back into the model.
Getting the package to the right address
Delivery is its own problem. A valuable package is ineffective if it cannot reach the correct address. The company's MET APFS concept is designed around configurable biological carrier structures, including exosome mimetics. In simple terms, the payload is the package, the carrier protects it, surface features help define an address, and computational outputs can inform how the carrier is configured for an intended destination. The platform is designed to accommodate multiple payload classes, potentially including proteins, peptides, and nucleic acid based cargo.
The individual patient
The final piece is the individual patient. No person is a population average. Two people with the same diagnosis can differ in genetics, metabolism, medications, environment, disease progression, and physiological response. The patent application therefore describes patient specific digital modeling and feedback within defined safety and authorization constraints. The long term concept is to move from asking what usually works for a group toward asking what is happening in this particular biological system, in this particular person, at this particular time.
The filing was developed by Boris Markosian, founder, CEO, and sole inventor of Instructional Biology Inc., pro se, following approximately fifteen years of work involving peptides, biological signaling, processing systems, and systems level approaches to medicine. The filing marks a transition from years of research and technology development toward broader development, validation, partnership discussions, and potential commercialization.
Open for partnership and licensing
The company said the five systems described in the application are available for discussion individually or as a whole, and that it is prepared to consider licensing, joint development and manufacturing partnerships. Complete portfolio documentation is available to qualified parties under a non-disclosure agreement. Inquiries may be directed through Partnerships & Licensing.
Instructional Biology emphasizes that a patent filing does not establish clinical efficacy, safety, regulatory approval, or the ability to treat any disease. Many elements of the platform require additional engineering, independent validation, manufacturing development, clinical investigation, and regulatory review. The patent application describes technologies and development objectives; it is not evidence that a therapeutic product has been approved or proven.
Instructional Biology believes these areas can be pursued as one integrated engineering and scientific program. The company refers to that program as Instructional Medicine.
About Instructional Biology Inc.
Instructional Biology Inc. is a biotechnology company based in Oceanside, CA, developing an integrated platform spanning computational biology, artificial intelligence, high fidelity bioprocessing, biological delivery systems, and patient specific therapeutic regulation. Its technology portfolio includes ASAP, SCKG, TSP, the Markosian High Fidelity Bio Processing protocol, nonthermal pathogen reduction concepts, MET APFS delivery technology, and patient specific computational feedback systems. More information is available at instructionalbiology.com.
Media and strategic inquiries
Instructional Biology Inc.
Boris Markosian, Founder, Inventor and CEO
instructionalbiologyinc@gmail.com
linkedin.com/in/boris-markosian